TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01264575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 9 mg with 100 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 10 mg with 100 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 11 mg with epinephrine 100 mcg
Description: intrathecal bupivacaine 11 mg with epinephrine 100 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 6 mg with 200 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 7 mg with 200 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 9 mg with 200 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 10 mg with 200 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
Description: intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
Study: NCT02692651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fidaxomicin
Description: Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
Study: NCT01929083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive oral placebo two capsules once daily every evening for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Study: NCT03415555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane blockade
Description: Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
Study: NCT04792450

Intervention type: DEVICE
Intervention: Tympanic Thermometer
Description: Measure Temperature using Tympanic Thermometer

Intervention type: DEVICE
Intervention: Tympanic Thermometer
Description: Measure Temperature using Tympanic Thermometer
Study: NCT01165710

Intervention type: OTHER
Intervention: Patients with Atrial Fibrillation (AF)
Description: Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
Study: NCT03415555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Each patient will generally anesthetized and endotracheal tube will be inserted

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Each patient will generally anesthetized and endotracheal tube will be inserted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol will be given i.v. every 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol will be given i.v. every 6 hours.
Study: NCT01305447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Behaviour Maintenance
Description: Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
Study: NCT04792450

Intervention type: DEVICE
Intervention: Forehead Thermometer
Description: Measure Temperature using Forehead Temperature

Intervention type: DEVICE
Intervention: Forehead Thermometer
Description: Measure Temperature using Forehead Temperature
Study: NCT01305447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Behaviour Maintenance
Description: Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Relapse prevention booklets
Description: Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Relapse prevention booklets
Description: Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact control
Description: No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
Study: NCT02717156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study: NCT05024006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Two intravenous loading doses, then daily infusion for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Two oral loading doses, then orally twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Orally twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: Orally twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Daily injection for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Daily injection for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Orally twice daily for 10 days
Study: NCT01812642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
Study: NCT03106532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-201 0.25% ophthalmic solution
Description: 3 drops daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-201 0.5% ophthalmic solution
Description: 3 drops daily, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Description: 3 drops daily, 28 days
Study: NCT04278794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Care Stroke Intervention (TCSI)
Description: Core components:~1. Comprehensive Hospital Discharge Plan. The Care Coordinator will meet with staff in the in-patient unit along with patients and their caregivers to develop and implement a comprehensive discharge plan.~2. Structured home visits and telephone support. As part of the structured home visits and telephone support, a member of the IP team will provide up to 6 home visits over 6 months. The team will provide: screening and assessment; medication review and reconciliation; self-management support; education; and caregiver assessment.~3. Monthly IP case conferences. 6 monthly IP team case conferences will be held to discuss goals identified by the patient, collectively develop a plan of care, and identify needs.~4. Linkages to services. Facilitate timely follow-up with the primary care provider and build relationships with local health and social service providers. These referrals and links will provide the foundation for continued use post-intervention.
Study: NCT00331760

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin

Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Study: NCT04574726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: static balance
Description: 30-second right and left unipodal static balance test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static balance
Description: 30-second right and left unipodal static balance test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dynamic balance
Description: for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic balance
Description: for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point
Study: NCT05911490

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged sitting
Description: In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking prolonged sitting
Description: In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
Study: NCT00809133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC6 given on day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Escalating dose cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: MTD dose of part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 given on Day 1 of 21 Day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC6 given on day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Escalating dose cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Escalating dose cohorts
Study: NCT01350869

Intervention type: DEVICE
Intervention: Xience
Description: Patients with Xience
Study: NCT00723333

Intervention type: PROCEDURE
Intervention: Reduced Intensity Conditioning (RIC) Allogenic Transplant
Description: Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
Study: NCT02459080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-4208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-4208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04792450

Intervention type: DEVICE
Intervention: 62 Max + Infra-red thermometer
Description: Measure Temperature using 62 Max + Infra-red thermometer

Intervention type: DEVICE
Intervention: 62 Max + Infra-red thermometer
Description: Measure Temperature using 62 Max + Infra-red thermometer
Study: NCT02731313

Intervention type: BIOLOGICAL
Intervention: Trastuzumab
Description: Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
Study: NCT03410238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Saferteens Brief Intervention
Description: A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
Study: NCT02727088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy
Description: ablation of the whole dental pulp, preparation and filling of the whole root canal system
Study: NCT03664037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline \[NS\]) intravenous infusion (IVI) over 15 min 2 hours preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
Study: NCT02692651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
Study: NCT04288232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal aflibercept Injection 2.0mg/0.05 ml
Study: NCT02146144

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM Peeling
Description: common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~* Central and peripheral 25 Gauge vitrectomy~* dissection of the epimacular membrane~* injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~* Intraoperative picture to see the possible spontaneous ILM peeling~* If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~* Arm 1: no peeling, where the ILM peeling will not be made~* Arm 2: active peeling, where the ILM peeling will be made
Study: NCT00115323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving
Description: Problem solving intervention
Study: NCT04074915

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouth rinse
Description: Normal saline
Study: NCT01429519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
Study: NCT00115323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention control intervention
Study: NCT05272436

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual Reality Upper Limb Motor Impairment Rehabilitation
Description: Patients wore a VR headset while undergoing their physical rehabilitation at home

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Upper Limb Motor Impairment Rehabilitation
Description: Patients wore a VR headset while undergoing their physical rehabilitation at home
Study: NCT01348009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel-capecitabine-cisplatin
Description: Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.
Study: NCT03288792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RI8 device imaging
Description: RI8 Device imaging for adjunctive detection of breast cancer
Study: NCT00216164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2, day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
Study: NCT02208778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 54 participants will be allocated for duloxetine treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 27 participants will be allocated to Remifentanil infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Remifentanil)
Description: Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Duloxetine)
Description: Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
Study: NCT02779361

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (\*), 10:30 am, 13:00 pm (\*), 15:30 pm, 18:00 pm (\*), 20:30 pm on day 7.~One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (\*).
Study: NCT01768429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatty fish

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lean Fish

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Study: NCT03967691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab infusion
Description: Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour
Study: NCT04074915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Description: Chlorhexidine gluconate
Study: NCT03967691

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: 100 ml NaCl 0.9% will be infused over 1 hour

Intervention type: DRUG
Group type: OTHER
Intervention: Saline 0.9%
Description: 100 ml NaCl 0.9% will be infused over 1 hour